Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.
9/25/18: “The sales momentum we are experiencing both domestically and internationally reinforces that we are successfully addressing the needs of people with diabetes worldwide,” said Kim Blickenstaff, President and Chief Executive Officer. “We are increasing our sales guidance as a reflection of this and the tremendous feedback we’ve been receiving on the t:slim X2 Insulin Pump.”
8/17/18: “This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care.
8/8/18: “The results seen in the PROLOG study demonstrate that an automated insulin delivery system can have a significant impact on glycemic control without being overly complicated or burdensome for the patient,” said Dr. Greg Forlenza, principal investigator for the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine.
4/30/18: Kim Blickenstaff, President and CEO of Tandem Diabetes Care stated, “As our first product to receive CE mark, this milestone is key to the fulfillment of our vision to bring the features and benefits of our unique insulin pump technology to people outside of the United States."
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), (a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States), announced the launch of the t:lock™ Connector for its insulin pump cartridges and infusion...
Medical Device News Magazine keeps our readers up-to-date on breaking medical device industry news and more!